Literature DB >> 889590

Pharmacokinetics and metabolism of vinblastine in humans.

R J Owellen, C A Hartke, F O Hains.   

Abstract

The pharmacokinetics of vinblastine in humans was examined using a radioimmunoassay specific for both the Vinca alkaloids and aromatic ring [3H]vinblastine. The data were consistent with a three-compartment open model system with the following values, alpha phase: t1/2=3.90+/-1.46 min; Vc=16.8+/-7.1 liters. beta phase:t1/2=53.0+/-13.0 min; Vbeta=79.0+/-52.0 liters; gamma phase:t1/2=1173.0+/-65.0 min; Vgamma=1656.0+/-717.0 liters. Most significant was the finding that vinblastine is metabolized to deacetylvinblastine and that this compound is more biologically active on a weight basis than the parent. No other biologically active metabolites appeared to be present in urine or in stool.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 889590

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  5-day vinblastine infusion for pancreatic adenocarcinoma. A phase II Southwest Oncology Group study.

Authors:  J T Guy; T Fleming; T W Pollock; S E Rivkin; R P Pugh; H Saiers; H E Hynes; J F Boyd
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

3.  Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids.

Authors:  T Nederman; J Carlsson
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Vinblastine and erythromycin: an unrecognized serious drug interaction.

Authors:  S W Tobe; L L Siu; S A Jamal; K L Skorecki; G F Murphy; E Warner
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Clinical pharmacokinetics of vindesine.

Authors:  R L Nelson; R W Dyke; M A Root
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.

Authors:  O van Tellingen; J H Beijnen; W J Nooijen; A Bult
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Concentration of vinblastine in human intracerebral tumor and other tissues.

Authors:  D J Stewart; K Lu; R S Benjamin; M E Leavens; M Luna; H Y Yap; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

8.  Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

Authors:  N H Greig; T T Soncrant; H U Shetty; S Momma; Q R Smith; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

Authors:  W H Steele; D J King; H E Barber; G M Hawksworth; A A Dawson; J C Petrie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 10.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.